Sign in7 stories
The Brisbane biotech named Nancy Freda-Smith to its board and Constance Ames as CFO while signing a $5 million-a-year services pact with CEO-linked Factor Bioscience.
SEC filing
The option, signed September 14, 2026, covers a BCMA/GPRC5D dual-targeting candidate now in Phase 1 for relapsed/refractory multiple myeloma.
SEC filing (2)
Justin Trojanowski resigns as Tempest's principal financial officer effective September 1, 2026, with Nicholas Rossettos stepping into the top finance role the same day.
SEC filing
The company could receive up to $50 million from Lincoln Park Capital under a purchase agreement, but only 8.9 million shares are being registered for resale now.
SEC filing
The August 13, 2026 agreement lets Tempest sell shares to Lincoln Park in stages over up to 24 months, subject to conditions and price limits.
SEC filing
Tempest ended the quarter with $0.8 million in cash and outlined plans for TPST-4003 dosing in China in the fourth quarter of 2026.
SEC filing
Tempest Therapeutics will work with China's Senlang Biotechnology to test TPST-4003 in myasthenia gravis and multiple sclerosis patients starting late 2026.
SEC filing